Joint venture · GCC · Announced 15 Apr 2026

Jerusalem Pharmaceuticals → Saudi investors

Palestine's Jerusalem Pharmaceuticals Group agreed to build a manufacturing plant in Saudi Arabia with Saudi investors, holding 70%, alongside a bonus share issue that doubles its capital to US$36 million.

Parties: Jerusalem Pharmaceuticals Group (Palestine) → Saudi investors (not named) (Saudi Arabia)

Deal type
Joint venture
Value
Undisclosed
Territory
Saudi Arabia
Therapeutic area
Multi-therapy
Asset
Pharmaceutical manufacturing plant
Announced
15 Apr 2026

Our analysis

Why this matters

On 15 April 2026, Jerusalem Pharmaceuticals Group (مجموعة القدس للمستحضرات الطبية) announced at its general assemblies an agreement to establish a pharmaceutical plant in Saudi Arabia in partnership with Saudi investors, with the group holding 70% and the Saudi partners 30%. The partners were not named and no investment amount or completion date was given. Shareholders also approved raising capital by US$18 million to US$36 million through capitalising retained earnings (a bonus issue), and a cash dividend of US$2.7 million.

The group reported 2025 net sales of US$48.95 million and net profit of US$10.26 million, and says it exports generics to 27 countries. It also opened a scientific office in the UAE and plans more than 18 new products.

The full analysis is free to read with a work email on this page.

Source: Raya (Palestine)

Latest deals

All GCC deals → · All joint venture deals → · Browse all emerging-market pharma deals →